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Abstract
Despite the central role of estrogen exposure in breast and endometrial cancer development and numerous studies of
genes in the estrogen metabolic pathway, polymorphisms within the pathway have not been consistently associated with
these cancers. We posit that this is due to the complexity of multiple weak genetic effects within the metabolic pathway
that can only be effectively detected through multi-variant analysis. We conducted a comprehensive association analysis of
the estrogen metabolic pathway by interrogating 239 tagSNPs within 35 genes of the pathway in three tumor samples. The
discovery sample consisted of 1,596 breast cancer cases, 719 endometrial cancer cases, and 1,730 controls from Sweden;
and the validation sample included 2,245 breast cancer cases and 1,287 controls from Finland. We performed admixture
maximum likelihood (AML)–based global tests to evaluate the cumulative effect from multiple SNPs within the whole
metabolic pathway and three sub-pathways for androgen synthesis, androgen-to-estrogen conversion, and estrogen
removal. In the discovery sample, although no single polymorphism was significant after correction for multiple testing, the
pathway-based AML global test suggested association with both breast (pglobal = 0.034) and endometrial (pglobal = 0.052)
cancers. Further testing revealed the association to be focused on polymorphisms within the androgen-to-estrogen
conversion sub-pathway, for both breast (pglobal = 0.008) and endometrial cancer (pglobal = 0.014). The sub-pathway
association was validated in the Finnish sample of breast cancer (pglobal = 0.015). Further tumor subtype analysis
demonstrated that the association of the androgen-to-estrogen conversion sub-pathway was confined to postmenopausal
women with sporadic estrogen receptor positive tumors (pglobal = 0.0003). Gene-based AML analysis suggested CYP19A1
and UGT2B4 to be the major players within the sub-pathway. Our study indicates that the composite genetic determinants
related to the androgen–estrogen conversion are important for the induction of two hormone-associated cancers,
particularly for the hormone-driven breast tumour subtypes.
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Introduction
Estrogen exposure is critical for the development of both breast
and endometrial cancers and represents the most well-established
risk factors for both diseases. Estrogen is a metabolic product
whose circulating level is determined by de novo synthesis,
conversion from other steroid hormones, and mechanisms of
estrogen elimination. These metabolic processes are regulated by a
network of enzymes encoded by different genes, suggesting that
genetic variation within these metabolic genes may impact on
breast and endometrial cancer risk. Genetic variation within the
estrogen metabolic pathway has been intensively investigated,
mostly by analyzing single variant effects in a limited number of
candidate genes, SNPs and study subjects. The inadequacies of
study design and analytical methodology have caused these studies
to be underpowered for detecting moderate genetic effects which,
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not surprisingly, has led to inconsistent results [1–8]. We surmised
that strategies for assessing the synergistic effect of multiple genetic
variants within the estrogen metabolic pathway may provide a
more realistic determination of genetic effect than a single gene,
single SNP approach.
Herein, we present a comprehensive analysis of genetic
variation in the estrogen metabolism pathway and its association
with breast and endometrial cancer risk using a pathway-based
approach.
Results
Single SNP Association Analysis
We performed single SNP association analysis in 1596 breast
cancer cases, 719 endometrial cancer cases and 1730 population
controls from Sweden. Of the 239 tagSNPs analyzed, 17 SNPs
(7.1%) had p-values less than 0.05 for breast cancer, and 18 SNPs
(7.5%) had p-values less than 0.05 for endometrial cancer (Table
S4 and Table S5). For breast cancer, the smallest p-value was
0.00034 at rs7167936 within CYP19A1, and for endometrial
cancer, the smallest p-value was 0.00017 at rs12595627 in
CYP19A1. The single-SNP associations were all moderate. Only
rs12595627 (for endometrial cancer) survived the conservative
Bonferroni correction for multiple testing at a=0.05. Overall,
however, the single-SNP p values appeared to deviate from their
null distribution of no association (formally tested below). The
single-SNP associations were suggestive, but instead of any single
variant having a strong effect, there appeared to be multiple weak
associations within the metabolic pathway.
Multi-SNP Pathway Analysis
To evaluate the cumulative effect from multiple variants we
employed the AML method [9] that assesses the experiment-wide
significance of association by analyzing multiple SNPs through a
single global test. The whole metabolic pathway can be sub-divided
into three a priori defined sub-pathways, each performing specific
metabolic function (Figure 1). Sub-pathway 1 is involved in the
synthesis of androgen, sub-pathway 2 is involved in the conversion of
androgens to estrogens, and sub-pathway 3 is responsible for
removing estrogens. To investigate whether there is multi-SNP
association for the whole pathway and whether any of the three sub-
pathways is particularly important in influencing disease risk, we
performed the progressive pathway-based global test on the whole
metabolic pathway as well as the three sub-pathways using the AML
method. The global test yielded marginally significant association for
the whole metabolic pathway in both breast (pglobal = 0.034) and
endometrial (pglobal = 0.052) cancers (Table 1). Dividing the
metabolic pathway into three functional sub-pathways for the global
test revealed strong association between the androgen-to-estrogen
conversion sub-pathway and both breast (pglobal = 0.008) and
endometrial (pglobal = 0.014) cancer (Table 1). The association
evidence survived correction for performing 4 pathway-based tests
in each cancer (pglobal corrected = 0.032 for breast and 0.056 for
endometrial). In contrast, the other two sub-pathways showed no
association with either form of cancer. For approximately half of the
Swedish subjects in the breast cancer study (797 cases and 764
controls) we have genome wide association study (GWAS) data
available. We used this to assess the possible influence of population
stratification on our results. For the GWAS dataset, the genomic
inflation factor, lgc, was1.015. Assuming an equal level of population
stratification (in terms of the fixation index FST) in the current study
and the GWAS sub-study, we estimated the genomic inflation factor,
lgc, to be 1.030 in the current study, using the relationship between
FST, sample size and lgc described in [10]. Using the lgc value of
1.030 for genomic control-based correction of population stratifica-
tion, the corrected global AML p-values for breast cancer are 0.052
for the entire pathway and 0.011 for the androgen-estrogen
conversion sub-pathway, leaving our results largely unchanged.
Even if lgc was as large as 1.05 in the current study, the global test
p-value for the androgen-estrogen conversion sub-pathway would
still be as low as 0.014. To further ensure that the observed
associations could not be due to the employment of 319 paraffin-
embedded tissue samples in the analysis, we re-ran analyses
excluding 319 paraffin-embedded tissue samples, and (at the same
time) excluding 33 SNPs with call rates of less than 95%. Results
were very similar. For example, for breast cancer, p-values were
0.028 and 0.009 for the entire pathway and for the androgen-
estrogen conversion sub-pathway, respectively. To validate the
association in the androgen-to-estrogen conversion sub-pathway, we
genotyped the 120 SNPs of this sub-pathway in an additional 2245
breast cancer cases and 1287 controls from Finland and performed
the same AML analysis by using the 118 successfully genotyped
SNPs. The validation analysis in the Finnish sample revealed similar
evidence of association between the androgen-to-estrogen conver-
sion sub-pathway and breast cancer (pglobal = 0.015) (Table 1). The
non-centrality parameter from the AML analysis of the androgen-to-
estrogen conversion sub-pathway, which represents the size of the
common effect of the associated SNPs, was estimated as 2.90 for the
Swedish sample and 2.94 for the Finnish sample. The similar values
indicate a consistent size of the genetic effect in the two samples. A
joint analysis of the Swedish and Finnish samples further yielded a
global p-value of 0.001 (Table 1). The SNPs with the lowest p-values
in the Finnish sample are listed in Table S6.
Analysis of the Androgen-to-Estrogen Conversion
Sub-Pathway in Breast Cancer Patient Subgroups
Hormone-related risk factors may play a differential role in
breast cancer subtypes. In particular, estrogens appear to drive the
development of ER positive tumors. This prompted us to
investigate the association in the androgen-to-estrogen conversion
sub-pathway in hormone-related breast tumor subtypes. As
Author Summary
Estrogen exposure is the most important risk factor for
breast and endometrial cancers. Genetic variation of the
genes involved in estrogen metabolism has, however, not
been consistently associated with these two cancers. We
posited that the genetic risk associated with the estrogen
metabolic genes is likely to be carried by multiple variants
and is therefore most effectively detected by multi-variant
analysis. We carried out a comprehensive association
analysis of the estrogen metabolic pathway by interrogat-
ing SNPs within 35 genes of the pathway in three tumor
samples from Sweden and Finland. Through pathway-
based multi-variant association analysis, we showed that
the genetic variation within the estrogen metabolic
pathway is associated with risk for breast and endometrial
cancers and that the genetic variation within the genes
involved in androgen-to-estrogen conversion is particular-
ly important for the development of ER–positive and
sporadic breast tumors in postmenopausal women. Our
study has demonstrated that the influence of genetic
variation on hormone exposure has an impact on breast
cancer development, especially on the development of
hormone-driven breast tumor subtypes. Our study has also
highlighted that future genetic studies of the estrogen
metabolic genes should focus on the androgen-to-
estrogen conversion process.
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surrogate markers for hormone driven tumour subtypes we
constructed variables as combinations of menopausal status,
family history and estrogen receptor (ER) status and divided all
the patients into subgroups. We then compared subgroups of
patients, defined on values of these variables, with controls, to
evaluate the role of the androgen-to-estrogen conversion sub-
pathway in different patient subgroups. First, we compared patient
subgroups against all the controls in the combined Swedish and
Finnish samples. The subgroup results showed that in the
combined samples, significant association was observed in
postmenopausal patients (pglobal = 0.009 and 0.018 respectively),
postmenopausal patients without family history (pglobal = 0.001 and
0.04 respectively), and postmenopausal patients with estrogen
receptor positive (ER+) tumors (pglobal = 0.0006 and 0.05 respec-
tively) (Table 2). No significant association was observed in either
premenopausal patients or postmenopausal patients with family
history or estrogen receptor negative (ER2) tumors.
Then, to rule out the possibility that the above subgroup results
were caused by the mismatch between the patient subgroups and the
controls in terms of the variables which defined patient subgroups,
Figure 1. Subdivision of the estrogenmetabolic pathway. This diagram shows how the 35 metabolic genes analysed in this study are involved
in different steps of the estrogen metabolism. It further shows how the genes are divided into the three groups involved in androgen synthesis,
estrogen synthesis and estrogen removal for sub-pathway-based association analysis.
doi:10.1371/journal.pgen.1001012.g001
Table 1. P values of the global tests of genetic association between the SNPs in the estrogen metabolic pathways and breast/
endometrial cancer risk.
Swedish Finnish Swedish and Finnish
Breast Cancer Endometrial Cancer Breast Cancer Breast Cancer
Whole Pathway (239 SNPs) 0.034 0.052 –
Androgen Synthesis (11 SNPs) 0.397 0.381 –
Androgen-Estrogen Conversion (120 SNPs)* 0.008 0.014 0.015 0.001
Estrogen Removal (144 SNPs)* 0.172 0.385 –
P-values were based on 2500 permutations.
*:36 SNPs are overlapped.
doi:10.1371/journal.pgen.1001012.t001
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we performed the second subgroup analysis where the controls were
also divided into subgroups according to family history and
menopausal status (Table 3). The second subgroup analysis was
only performed in the Swedish sample, because the Finnish controls
lack information on family history and menopausal status. This
yielded similar evidence for the association of the sub-pathway with
the hormone-driven subtypes of breast cancer as in Table 2.
Analysis of Reproductive Risk Factors’ Impact on the
Association of the Androgen-to-Estrogen Conversion
Sub-Pathway with Breast Cancer
We further investigated the impact of reproductive risk factors on
the genetic association of the androgen-to-estrogen conversion sub-
pathway with breast cancer. Because the risk factor information is
not available for the Finnish controls, the analysis of the reproductive
risk factors was performed in the Swedish samples where information
on such factors is available. We performed the AML analysis of the
androgen-to-estrogen conversion sub-pathway with adjustment for
the reproductive risk factors (parity, age at the first birth, age at
menarche and age of menopause) and HRT use. We investigated
this primarily to assess whether any of the reproductive risk factors
could be in the causal pathway. Since p-values remained almost
unchanged in all analyses (Table 4), it appears that none of the
reproductive risk factors are likely to be in the causal pathway.
Gene-Based Analysis of the Androgen-to-Estrogen
Conversion Sub-Pathway in Breast and Endometrial
Cancers
Attempting to refine the association within the androgen-to-
estrogen conversion sub-pathway, we performed a gene-based
AML analysis in the combined Swedish/Finnish breast cancer
sample and the Swedish endometrial cancer sample. Among the
15 genes tested (Table 5), strong association was observed for
CYP19A1 with both breast (pglobal = 0.003) and endometrial
(pglobal = 0.006) cancer and UGT2B4 (pglobal = 0.002) with breast
cancer only. The associations in breast cancer survived correction
for multiple testing of 15 genes (pglobal corrected = 0.045 for CYP19A1
and 0.03 for UGT2B4). We also observed suggestive association for
UGT2B11 in breast and endometrial cancer as well as for
HSD11B1, SULT2A1 and SULT2B1 in breast cancer. Consistent
with the pathway-based associations, the gene-based associations
are generally more significant in sporadic postmenopausal patient
samples than in the whole breast cancer sample (except SULT2B1).
Furthermore, the importance of CYP19A1 and UGT2B4 in breast
cancer risk is supported by the fact that excluding either gene from
the global test of the sub-pathway reduced the global significance
of association for the sub-pathway, from 0.0015 to 0.011 for
CYP19A1, and to 0.010 for UGT2B4. However, the fact that the
association for the sub-pathway remained significant, after
excluding either gene, suggests that, although CYP19A1 and
UGT2B4 are the major players, genetic variation within other
genes also contributes to the association within the sub-pathway.
Discussion
Our pathway-based multi-SNP association analysis revealed a
significant association between genetic variants in the androgen-
to-estrogen conversion sub-pathway and the risk of two hormone
dependent cancers. The association was particularly strong for
ER+, sporadic breast cancer. Single SNP analysis did not reveal a
similar association. We used the AML-based multi-SNP analysis,
Table 2. Patient subgroup analysis of the androgen-to-estrogen conversion sub-pathway.
All Cases Menopausal Status Family History ER Status
Pre Post (PM) PM Familial PM Sporadic (PMS) PMS ER+ PMS ER2
Swedish Sample # controls 1518
# cases 1555 – 1545 244 1260 661 183
Pglobal 0.008 – 0.009 0.23 0.001 0.0006 0.65
Finnish Sample # controls 1287
# cases 2245 498 1176 313 853 704 137
Pglobal 0.015 0.10 0.018 0.43 0.040 0.050 0.36
Joint AML Analysis # controls 2805
# cases 3800 498 2721 557 2113 1365 320
Pglobal 0.001 0.10 0.002 0.33 0.0005 0.0003 0.57
All the Pglobal values are based on 5,000 permutations and reflect comparisons of various patient subgroups with all the controls.
doi:10.1371/journal.pgen.1001012.t002
Table 3. Subgroup analysis of the androgen-to-estrogen conversion sub-pathway in the Swedish samples.
All Cases Menopausal Status Family History ER Status
Pre Post (PM) PM Familial PM Sporadic(PMS) PMS ER+ PMS ER2
# controls 1518 1505 128 1253 1253 1253
# cases 1555 – 1545 244 1260 661 183
Pglobal 0.008 – 0.009 0.896 0.002 0.001 0.618
P-values for tests using PMS ER+ and PMS ER2 patient sub-groups are based on comparisons with 1253 PMS controls.
doi:10.1371/journal.pgen.1001012.t003
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which has been shown to be more powerful than single SNP tests
to yield significant and consistent association, when genetic risk is
carried by multiple risk alleles each with moderate effect [11].
Pathway-based approaches are just beginning to be applied in
association analysis [12]. Recently, an association study of 9
candidate gene groups (involving 120 candidate genes) was
performed in breast cancer by using the AML approach, and
interestingly, only the group of 8 genes involved in the steroid
hormone signalling were significantly associated [13]. Our study
has moved one step further and highlights the fact that the power
of the pathway-based association analysis can be increased when
analysis is guided by well-defined biological information. We
believe that pathway approaches have potential to move genome-
wide association studies beyond their initial success of identifying
some ‘low-hanging fruits’ to revealing many weak genetic risk
alleles that have been missed by single SNP analysis.
Unless one enzyme is the rate limiting step for the entire
metabolic pathway, it is not likely that small functional
perturbations of individual variants would have a major impact
on the overall effect of the metabolic pathway. To test the
hypothesis that several genetic variants, each conferring weak to
moderate effects, contribute to genetic risk, we adopted a
systematic pathway-based approach for association analysis by
testing the joint effect of multiple genetic variants in a progressive
fashion from the whole metabolic pathway to biochemical sub-
pathways and further down to individual genes. Such a progressive
approach allows us to not only establish consistent association in
three cancer samples from two different populations but also to
refine the association of the androgen-to-estrogen conversion
component of the metabolic pathway. Our study may therefore
have advanced our understanding of the role of estrongen
metabolism in breast and endometrial cancers by 1) accounting
for the ambiguity surrounding the genetic association results and
2) indicating the androgen-to-estrogen conversion to be the
important component of the metabolic pathway in modulating
the risk and therefore to be a worthy focus for future studies.
After menopause, ovarian estrogen production dramatically
declines and conversion of adrenal androgens to estrogens in
peripheral tissues becomes the major source of circulating
estrogens. The final step of this conversion is catalyzed by
aromatase, encoded by CYP19A1 [11]. Thus, there is biological
plausibility in the association between CYP19A1 polymorphisms
and postmenopausal breast cancer. Moreover, pharmacological
inhibition of aromatase prevents recurrences in postmenopausal
women with estrogen-receptor-positive breast cancer and new
contralateral primaries [14], which has challenged the previous
routine of a 5-year course of tamoxifen alone [15]. Our study has
advanced our understanding of CYP19A1 by suggesting that the
modulation of aromatase activity by either germ-line variation or
pharmacological agents can influence the development of ER+
tumour in postmenopausal women. Furthermore, the convergence
of genetic and pharmacological effects of CYP19A1 also raises
therapeutic possibilities. For example, other genes implicated by
our genetic study, such as UGT2B4, might also be pharmacolog-
ical targets for treating breast cancer.
Hormone exposure is a common risk factor for breast and
endometrial cancer. Our employment of the three samples of two
different hormone-related cancers from two different populations
allowed us to apply a very stringent criterion for declaring an
Table 4. Pglobal values for the androgen-to-estrogen sub-pathway for all cases and for PMS ER+ cases in the Swedish sample set,
adjusted for reproductive and hormone risk factors.
Adjusted Reproductive Variables All cases PMS ER+
Sample Size (case/control) Pglobal Sample Size (case/control) Pglobal
Unadjusted 1555/1518 0.008 661/1518 0.0006
HRT use* 1541/1493 0.005 651/1493 0.0008
Parity* 1555/1518 0.0088 661/1518 0.0014
Age at first birth* 1323/1370 0.0176 563/1370 0.0016
Age at menarche* 1411/1390 0.0036 595/1390 0.0004
Age at menopause* 1545/1505 0.0102 658/1505 0.0016
*: HRT use, the AML Pglobal values were adjusted by a categorical variable, HRT/nonHRT. Similarly, Parity, adjusted by none/one or more children; Age at first time
birth, adjusted by ,25yrs, 25–30yrs, 30–35yrs and.= 35yrs; Age at menarche, adjusted by.= 14yrs, 12–13yrs and,= 12yrs; Age at menopause, adjusted by ,45yrs,
45–50yrs, 50–55yrs and .= 55yrs. All AML Pglobal values are based on 5,000 permutations. PMS: postmenopausal and sporadic.
doi:10.1371/journal.pgen.1001012.t004
Table 5. Gene-based AML Pglobal values for the 15 genes
within the androgen-to-estrogen conversion sub-pathway.
Genes # SNPs Breast Cancer * Endometrial
All Cases PMS PMS ER+ Cancer
AKR1C4 11 0.121 0.098 0.113 0.729
CYP11B1 2 0.595 0.692 0.619 0.663
CYP11B2 4 0.390 0.496 0.665 0.863
CYP19A1 15 0.006 0.003 0.013 0.006
HSD11B1 9 0.181 0.125 0.026 0.701
HSD11B2 6 0.130 0.244 0.096 0.778
HSD3B1 7 0.549 0.551 0.108 0.065
SRD5A1 5 0.870 0.852 0.851 0.325
SRD5A2 7 0.267 0.151 0.190 0.265
STS 9 0.393 0.582 0.997 0.806
SULT2A1 8 0.332 0.040 0.080 0.535
SULT2B1 12 0.028 0.190 0.193 0.784
UGT1A1-9 12 0.378 0.413 0.205 0.888
UGT2B11 7 0.179 0.078 0.027 0.047
UGT2B4 7 0.002 0.003 0.003 0.31
*:PMS, Postmenopausal Sporadic Cases; PMS ER+, Postmenopausal Sporadic
Cases with ER+ tumors; the AML Pglobal values for breast cancer were based on
both the Swedish and Finnish samples and calculated using Fisher’s method. All
AML Pglobal values are based on 5,000 permutations.
doi:10.1371/journal.pgen.1001012.t005
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association. Furthermore, results of our breast cancer patient
subgroup analysis indicate that the genetic determinants within the
androgen-to-estrogen conversion sub-pathway may play a more
prominent role in postmenopausal women with sporadic ER+
tumors, further suggesting that the modulation of hormone
exposure by genetic variation may have a differential impact on
breast tumor subtypes. Endogenous sex hormone level appears to
be associated with breast cancer risk in postmenopausal women
[16], and particularly with the risk of ER+/PR+ breast tumors
[17]. The effect of hormone-related factors on breast cancer risk
apparently differs by ER status [18] and menopause status [19,20].
It could also differ by the status of family history of the disease, as
suggested by a recent study showing that most cases of hereditary
breast cancer are probably not related to cumulative hormone
exposure [21]. Our findings may have therefore advanced the
development of a general model for breast cancer risk: hormonal
factors, both genetic and reproductive, can play a key role in the
genesis of post-menopausal and ‘‘sporadic’’ breast cancer, whereas
genes involved in DNA repair, checkpoints, and genetic stability
(such as BRCA1, BRCA2, p53, ATM, CHK2) appear to be more
involved in predominantly breast cancers associated with family
history of disease.
It is worth noting that the contribution of genetic polymor-
phisms to risk is a function of both their prevalence and
penetrance and thus the relative importance of individual SNPs
may vary from population to population. More studies in different
populations are needed to fully understand the role of the
androgen-to-estrogen conversion sub-pathway in breast cancer.
We also want to highlight that our results are of genetic association
in nature, and further studies are needed to confirm the findings
and to identify functional variants causally linked to cancer risk.
Materials and Methods
Study Subjects
Swedish subjects were from a population-based case control
study of breast and endometrial cancer as described [22,23].
Briefly, the study included all incident primary invasive breast and
endometrial cancers among Swedish-born postmenopausal wom-
en between 50 and 74 years of age at diagnosis, diagnosed with
breast cancer between October 1993 and March 1995 and
endometrial cancer between January 1994 and December 1995.
All cases were identified through six regional cancer registries in
Sweden, and all controls were randomly selected from the Swedish
Registry of Total Population and frequency matched to the
expected age distribution of the cases.
Finnish breast cancer cases consist of two series of unselected
breast cancer patients and additional familial cases ascertained at
the Helsinki University Central Hospital. The first series of 884
patients was collected in 1997–1998 and 2000 and covers 79% of all
consecutive, newly diagnosed cases during the collection periods
[24,25]. The second series, containing 986 consecutive newly
diagnosed patients, was collected in 2001–2004 and covers 87% of
all such patients treated at the hospital during the collection period
[26]. An additional 538 familial breast cancer cases were collected at
the same hospital as described [27–30]. 1287 anonymous, healthy
female population controls were collected from the same geograph-
ical regions in Southern Finland as the cases and have been used in
several studies previously [31–33].
Risk factor information and tumour characteristics were
available for all the Swedish samples and the Finnish cases, but
were missing for the Finnish controls. The Finnish samples (mean
age = 56 for the cases and 41 for the controls) were younger than
the Swedish samples (mean age = 63 for both the cases and
controls). All the risk factor and tumour characteristics information
of the subjects are summarized in Table S1 and Table S2.
Written informed consent was obtained from all participating
subjects, and the study was approved by the Institutional Review
Boards in Sweden, Finland and at the National University of
Singapore.
DNA Isolation
DNA was extracted from 4 ml of whole blood using the
QIAamp DNA Blood Maxi Kit (Qiagen)and non-malignant cells
in paraffin-embedded tissue using a standard phenol/chloroform/
isoamyl alcohol protocol [34].
Gene and SNP Selection
We selected 35 genes involved in estradiol or estrone
metabolism and expressed in the breast (based on published
literatures). We selected 1007 single nucleotide polymorphisms
(SNPs) in these genes and their 30kb flanking sequences from the
dbSNP (build 124) and Celera databases, aiming for a marker
density of at least one SNP per 5kb (Table S3). These SNPs were
genotyped in 92 Swedish control samples to assess linkage
disequilibrium pattern and coverage. Haplotypes were recon-
structed using the PLEM algorithm [35] implemented in the
tagSNPs program [36]. A subset of SNPs, tagSNPs, were selected
based on the R2 coefficient, which quantifies how well the tagSNP
haplotypes predict the genotype or haplotypes an individual
carries. We chose tagSNPs so that common SNP genotypes and
haplotypes (frequency $0.03) were predicted with R2$0.8 [37].
To evaluate our tagSNPs’ performance in capturing unobserved
SNPs within the genes, we performed a SNP-dropping analysis
[38,39]. In brief, each of the genotyped SNPs was dropped in turn
and tagSNPs were selected from the remaining SNPs so that their
haplotypes predicted the remaining SNPs with an R2 value of 0.85.
We then estimated how well the tagSNP haplotypes of the
remaining SNPs predicted the dropped SNP, an evaluation that
can provide an unbiased and accurate estimate of tagSNP
performance [38,39]. Overall, we selected and genotyped 302
tagSNPs from the 35 genes in all the Swedish cases and controls.
Genotyping
Genotyping was performed using the Sequenom system (San
Diego, California). All genotyping results were generated with
positive and negative controls and checked by laboratory staff
unaware of case-control status. Of the 302 tagSNPs, 42 SNPs failed
in the development stage of Sequenom genotyping assays. SNPs with
a call rate,85% (8 SNPs), minor allele frequency,1% (9 SNPs) or
out of Hardy-Weinberg Equilibrium (p,0.05/252, 4 SNPs) were
excluded from further analysis. Overall, 239 tagSNPs from the 35
genes were successfully genotyped (Table S3). The genotype
concordance was .99%, suggesting high genotyping accuracy.
Statistical Analysis
The Cochran-Armitage trend test was performed for each of the
239 SNPs. One approach for assessing the departure of the
distribution of the (Cochran-Armitage) test statistics from the
(global) null distribution (no SNPs associated) has been described
by Tyrer et. al. [9]. The approach is based upon fitting a mixture
model to the distribution of the test statistics, with two
components, one representing SNPs which are independent of
the case-control status, the other representing SNPs associated
with case-control status. The Cochran-Armitage test statistics for
the associated SNPs are assumed to all have the same (chi-squared)
non-centrality parameter value. The distributed software for the
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‘‘admixture maximum likelihood’’ (AML) test of Tyrer et. al. [9]
calculates empirical p-values based on a ‘‘pseudo-likelihood ratio’’
test, comparing the ratio of values of the optimized likelihoods
under the null and alternative hypotheses for the observed data,
with the corresponding values obtained from a large number of
data sets with case-control status permuted randomly. It also
provides an estimate of the non-centrality parameter which is a
measure of the common effect size of the associated SNPs within
the pathway. We performed the AML-based global test of
association for the full metabolic pathway as well as for 3 sub-
pathways (see results section). In addition, we performed gene-
specific analyses, using the AML-based global test on SNPs within
genes, within the androgen-estrogen conversion sub-pathway. We
also carried out AML tests adjusted for a non-genetic risk factor
using software provided by the authors of Tyrer et al. [9].
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